Amylyx (AMLX) Pharmaceuticals announced that the last participant has been randomized and dosed in the Phase 3 Lucidity clinical trial of avexitide. Lucidity is a 16-week, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of avexitide in adults with PBH following Roux-en-Y gastric bypass surgery. Participants who complete the 16-week double-blind period are eligible to enter a 32-week open-label extension period. The trial has enrolled 78 participants, with topline data readout anticipated in Q3 2026. If approved, commercial launch of avexitide is anticipated in 2027.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx price target raised to $30 from $25 at Guggenheim
- Buy Rating on Amylyx Pharmaceuticals Driven by Avexitide’s Commercial Potential and De-Risked Phase III PBH Program
- Amylyx Pharmaceuticals Maps High-Stakes Path to 2027
- Amylyx price target raised to $34 from $28 at H.C. Wainwright
- Amylyx Pharmaceuticals: Solid Balance Sheet, Advancing Pipeline, and Attractive Risk‑Reward Support Buy Rating